natgillin/translations-raw huggingface dataset:
• if you currently have an infection 
• če trenutno prebolevate okužbo
• if you are taking, have recently taken or might take any other medicines. 
• če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo,
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the Instructions for Use in the package leaflet. 
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6 in Navodila za uporabo v priloženem navodilu.
Chemical and physical in-use stability has been demonstrated for 24 hours at 2ºC to 8ºC. 
Kemijsko in fizikalno stabilnost pripravljenega zdravila so dokazali za 24 ur pri 2 °C do 8 °C.
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data). 
Pri tem ustrezna kategorija pogostnosti posameznega neželenega učinka temelji na naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Week 24 
teden 24
Improvements in HAQ-DI scores were seen regardless of previous anti-TNFα exposure. 
Izboljšanje ocene HAQ-DI so opažali ne glede na predhodno izpostavljenost zaviralcu TNFα.
Then talk to your doctor to discuss when you should inject the next dose. 
Nato se posvetujte z zdravnikom, kdaj si morate injicirati naslednji odmerek.
YOU MUST READ THIS BEFORE INJECTING. 
TO MORATE PREBRATI PRED INJICIRANJEM
This is intended to aid in the protection of healthcare professionals, patients who self-inject doctor-prescribed medicines, and individuals who assist self-injecting patients from accidental needlestick injuries. 
To je namenjeno zaščiti zdravstvenih delavcev, bolnikov, ki si sami injicirajo zdravila, ki jim jih predpiše zdravnik, in oseb, ki bolnikom pomagajo pri samoinjiciranju, pred poškodbami zaradi nehotenega vboda z iglo.
• infection of the external ear (otitis externa) 
• vnetje zunanjega ušesa (otitis externa)
The safety profile of secukinumab is consistent across all indications. 
Varnostni profil sekukinumaba je podoben pri vseh indikacijah.
Cosentyx can potentially cause serious side effects, including infections and allergic reactions. 
Zdravilo Cosentyx lahko povzroči resne neželene učinke, med drugim okužbe in alergijske reakcije.
If you have active psoriatic arthritis you will first be given other medicines. 
Če imate aktiven psoriatični artritis, boste najprej prejemali druga zdravila.
The preparation of the solution for subcutaneous injection must be done without interruption and ensuring that aseptic technique is used. 
Pripravljanje raztopine za subkutano injiciranje mora potekati brez prekinitev, izvajati pa ga je treba z aseptično tehniko.
Clinically important, active infection, e.g. active tuberculosis (see section 4.4). 
Klinično pomembna aktivna okužba, na primer aktivna tuberkuloza (glejte poglavje 4.4).
The stream of sterile water for injections should be directed onto the powder. 
Tok sterilne vode za injekcije mora biti usmerjen na prašek.
** p values versus etanercept: p=0.0250 
** vrednost p v primerjavi z etanerceptom: p=0,0250
Similar responses were seen in PsA study 1. 
Podobne odzive so opažali tudi v PsA študiji 1.
These improvements were sustained up to week 52. 
Ta izboljšanja so se ohranila do konca 52. tedna.
Women of childbearing potential should use an effective method of contraception during treatment and for at least 20 weeks after treatment. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še najmanj 20 tednov po njem.
• if you are allergic to secukinumab or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na sekukinumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The data suggest that secukinumab does not suppress the humoral immune response to the meningococcal or influenza vaccines. 
Podatki kažejo, da sekukinumab ne zavira humoralnega imunskega odziva na meningokokno cepivo oziroma cepivo proti gripi.
The majority of patients also had active psoriasis skin lesions or a documented history of psoriasis. 
Večina bolnikov je imela tudi aktivne psoriatične kožne lezije ali dokumentirano anamnezo psoriaze.
If you have ankylosing spondylitis you will first be given other medicines. 
Če imate ankilozirajoči spondilitis, boste najprej prejemali druga zdravila.
• swelling of the face, lips, tongue or throat 
• otekanje v obraz, ustnice, jezik ali grlo oziroma žrelo,
The efficacy and safety of secukinumab 150 mg and 300 mg were evaluated versus either placebo or etanercept. 
Učinkovitost in varnost sekukinumaba v odmerkih 150 mg in 300 mg so vrednotili v primerjavi z bodisi placebom ali etanerceptom.
The effect of secukinumab on human fertility has not been evaluated. 
Vpliva sekukinumaba na plodnost pri ljudeh niso ocenjevali.
For storage conditions after reconstitution of the medicinal product, see section 6.3 
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Not known (frequency cannot be estimated from the available data): • fungal infections of the skin and mucous membranes (including oesophageal candidiasis) 
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov): • glivične okužbe kože in sluznic (vključno s kandidozo požiralnika)
9/l (CTCAE grade 4) were reported. 
9/l (stopnje 4 po CTCAE).
Do not use Cosentyx: 
Ne uporabljajte zdravila Cosentyx:
Any remaining solution in the vial must not be used and should be discarded in accordance with local requirements. 
Morebitnega preostanka raztopine v viali ne smete uporabiti, ampak ga morate zavreči v skladu z lokalnimi zahtevami.
Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC10 
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci interlevkinov, oznaka ATC: L04AC10
Cosentyx reduces the inflammation and other symptoms of the disease. 
Zdravilo Cosentyx zmanjšuje vnetje in druge simptome bolezni.
Concomitant immunosuppressive therapy 
Sočasno imunosupresivno zdravljenje
The powder for solution for injection must be reconstituted before use. 
Prašek za raztopino za injiciranje je treba pred uporabo rekonstituirati.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj, razen če metoda rekonstitucije izključuje tveganje za kontaminacijo z mikrobi.
Allow the vial to stand undisturbed at room temperature for approximately 5 minutes. 
Vialo pustite mirovati na sobni temperaturi približno 5 minut.
Effect of weight on pharmacokinetics Secukinumab clearance and volume of distribution increase as body weight increases. 
Vpliv telesne mase na farmakokinetiko Očistek in volumen porazdelitve sekukinumaba se povečujeta z večanjem telesne mase.
If you have forgotten to inject a dose of Cosentyx, inject the next dose as soon as you remember. 
Če ste si pozabili injicirati odmerek zdravila Cosentyx, si naslednji odmerek injicirajte takoj, ko to ugotovite.
Forty percent of the participants in studies 1 and 2 completed the Psoriasis Symptom Diary©. 
Štirideset odstotkov preiskovancev v 1. in 2. študiji je izpolnjevalo dnevnik simptomov psoriaze (Psoriasis Symptom Diary©).
What Cosentyx is and what it is used for 
Kaj je zdravilo Cosentyx in za kaj ga uporabljamo
Table 3 Summary of clinical response on psoriasis study 2 (FIXTURE) 
Preglednica 3 Pregled kliničnih odzivov v 2. študiji psoriaze (v študiji FIXTURE)
It is not known whether secukinumab is excreted in human milk. 
Ni znano, ali se sekukinumab izloča v materino mleko.
Patients should be instructed to inject the full amount of Cosentyx according to the instructions provided in the package leaflet. 
Bolnikom je treba naročiti, naj si injicirajo celotno količino zdravila Cosentyx po navodilih v priloženem Navodilu za uporabo.
• if you are receiving any other treatment for psoriasis, such as another immunosuppressant or phototherapy with ultraviolet (UV) light. 
• če prejemate še katerega od zdravil za psoriazo, kot so druga imunosupresivna zdravila, ali se zdravite s fototerapijo (obsevanjem z ultravijoličnimi (UV) žarki).
Based on population pharmacokinetic analysis with a limited number of elderly patients (n=71 for age ≥65 years and n=7 for age ≥75 years), clearance in elderly patients and patients less than 65 years of age was similar. 
Po rezultatih analize populacijske farmakokinetike pri majhnem številu starejših bolnikov (n=71 za starost ≥65 let in n=7 za starost ≥75 let) je bil očistek pri starejših bolnikih podoben kot pri bolnikih, ki so bili stari manj kot 65 let.
Patients randomised to “retreatment as needed” did not achieve adequate maintenance of response and therefore a fixed monthly maintenance regimen is recommended. 
Pri bolnikih, ki so bili randomizirani na zdravljenje po režimu "ponovitve zdravljenja po potrebi", se odziv na zdravljenje ni ohranil v zadostni meri, zato se priporoča zdravljenje po vzdrževalnem režimu z rednim mesečnim odmerjanjem zdravila.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. 
Zdravilo Cosentyx je namenjeno uporabi po navodilih in pod nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere je indicirano zdravilo Cosentyx.
Other medicines and Cosentyx 
Druga zdravila in zdravilo Cosentyx
Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks. 
Pri tistih bolnikih, pri katerih sprva pride le do delnega odziva, se ta lahko kasneje izboljša, če bolnik prejema zdravilo več kot 16 tednov.
Figure 1 Time course of percentage change from baseline of mean PASI score in study 1 (ERASURE) 
Slika 1 Časovni potek odstotne spremembe povprečne vrednosti indeksa PASI od izhodišča v 1. študiji (študiji ERASURE)
• burning sensation when passing urine. 
• pekočo bolečino pri odvajanju urina.
In a study in subjects with plaque psoriasis, no interaction was observed between secukinumab and midazolam (CYP3A4 substrate). 
V študiji pri bolnikih s psoriazo v plakih niso opažali nobenih interakcij med sekukinumabom in midazolamom (substrat CYP3A4).
Immunoglobulins are excreted in human milk and it is not known if secukinumab is absorbed systemically after ingestion. 
Imunoglobulini se izločajo v materino mleko, ni pa znano, ali se sekukinumab po zaužitju sistemsko absorbira.
Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. 
Sekukinumab je rekombinantno popolnoma humano monoklonsko protitelo, pridobljeno s pomočjo ovarijskih celic kitajskega hrčka (celic CHO).
• lower respiratory tract infections 
• okužbe spodnjih dihal,
If an anaphylactic or other serious allergic reactions occur, administration of secukinumab should be discontinued immediately and appropriate therapy initiated. 
Če pride do anafilaktičnih ali drugih resnih alergijskih reakcij, je treba zdravljenje s sekukinumabom takoj prekiniti in uvesti ustrezno zdravljenje.
(nasopharyngitis, rhinitis) 
(nazofaringitis in rinitis).
In psoriasis phase 3 clinical studies, neutropenia was more frequently observed with secukinumab than with placebo, but most cases were mild, transient and reversible. 
V kliničnih študijah psoriaze faze 3 so nevtropenijo pri uporabi sekukinumaba opažali pogosteje kot pri uporabi placeba, vendar je bila v večini primerov blago izražena, prehodna in reverzibilna.
• warm, red and painful skin, or a painful skin rash with blisters 
• vročo, rdečo in bolečo kožo ali boleč kožni izpuščaj z mehurčki,
Cosentyx is used for the treatment of the following inflammatory diseases: 
Zdravilo Cosentyx uporabljamo pri zdravljenju naslednjih vnetnih bolezni:
• if you have recently had a vaccination or if you are due to have a vaccination during treatment with Cosentyx. 
• če ste bili pred kratkim cepljeni ali če morate prejeti cepivo v času zdravljenja z zdravilom
IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. 
IL-17A je naravno prisoten citokin, ki sodeluje pri normalnem vnetnem in imunskem odzivu.
Table 4 Summary of clinical response on CLEAR study 
Preglednica 4 Pregled kliničnih odzivov v študiji CLEAR
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately. 
V primeru prevelikega odmerjanja je priporočeno bolnika opazovati glede morebitnega pojavljanja znakov ali simptomov neželenih učinkov in v tem primeru takoj uvesti simptomatsko zdravljenje.
ASAS 5/6, % 
odziv ASAS 5/6, %
For other psoriatic arthritis patients: 
Za druge bolnike s psoriatičnim artritisom:
Consideration should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment. 
Pri bolnikih, pri katerih v 16 tednih zdravljenja ne pride do odziva, je treba razmisliti o prenehanju zdravljenja.
Because of the potential for adverse reactions in nursing infants from secukinumab, a decision on whether to discontinue breast-feeding during treatment and up to 20 weeks after treatment or to discontinue therapy with Cosentyx must be made taking into account the benefit of breast-feeding to the child and the benefit of therapy to the woman. 
Zaradi možnosti razvoja neželenih učinkov sekukinumaba pri dojenem otroku se je treba odločiti, ali bo bolnica prenehala z dojenjem v času zdravljenja in obdobju 20 tednov po zaključku zdravljenja ali bo prekinila zdravljenje z zdravilom Cosentyx, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Patients receiving secukinumab may receive concurrent inactivated or non-live vaccinations. 
Bolniki, ki prejemajo sekukinumab, so lahko sočasno cepljeni z inaktiviranimi ali drugimi cepivi, ki niso živa.
Animal studies have not been conducted to evaluate the carcinogenic potential of secukinumab. 
Za oceno kancerogenega potenciala sekukinumaba niso izvajali študij na živalih.
CARTON - vial 
ŠKATLA - viala
Do not shake or invert the vial. 
Viale ne stresajte in ne obračajte.
Neutropenia <1.0-0.5x10 
O nevtropeniji z vrednostmi <1,0-0,5 x 10
For both studies, the primary endpoint was at least a 20% improvement in Assessment of Spondyloarthritis International Society (ASAS 20) criteria at week 16. 
V obeh študijah je bil primarni cilj študije najmanj 20-odstotno izboljšanje ocene ASAS (ASAS 20) po kriterijih Mednarodnega združenja za spondiloartritis (ASAS - Assessment of Spondyloarthritis International Society) po 16 tednih zdravljenja.
IgGs are mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance of secukinumab. 
Protitelesa IgG se izločajo večinoma s pomočjo katabolizma in ni pričakovati, da bi okvara jeter lahko vplivala na izločanje sekukinumaba iz telesa.
Patients in Ankylosing Spondylitis study 1 (AS study 1) and Ankylosing Spondylitis study 2 (AS study 2) had a diagnosis of AS for a median of 2.7 to 5.8 years. 
Pri bolnikih v študiji ankilozirajočega spondilitisa 1 (AS študiji 1) in študiji ankilozirajočega spondilitisa 2 (AS študiji 2) je bila mediana časa od postavitve diagnoze ankilozirajočega spondilitisa 2,7 do 5,8 let.
Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. 
Bolnikom je treba naročiti, da se posvetujejo z zdravnikom, če opazijo znake ali simptome, ki kažejo na okužbo.
How much Cosentyx is given and for how long Your doctor will decide how much Cosentyx you need and for how long. 
Koliko zdravila Cosentyx je treba dajati in kako dolgo Koliko zdravila Cosentyx potrebujete in kako dolgo, bo določil vaš zdravnik.
If you think you may be allergic, ask your doctor for advice before using Cosentyx. 
Če menite, da bi lahko bili alergični, se pred začetkom uporabe zdravila Cosentyx posvetujte z zdravnikom.
What you need to know before you use Cosentyx 
Kaj morate vedeti, preden boste uporabili zdravilo Cosentyx
methionine, polysorbate 80 and water for injections. 
polisorbat 80 in voda za injekcije.
Table 6 Change in modified Total Sharp Score in psoriatic arthritis 
Preglednica 6 Sprememba modificirane skupne Sharpove ocene pri psoriatičnem artritisu
Approximately 15 to 25% of patients in phase III studies had psoriatic arthritis (PsA) at baseline. 
Približno 15 do 25 % bolnikov v študijah faze III je imelo ob izhodišču psoriatični artritis.
Patient Instructions for Use 
Navodila za uporabo za bolnike
Secukinumab has been shown to lower (within 1 to 2 weeks of treatment) levels of C-reactive protein, which is a marker of inflammation. 
Dokazali so, da sekukinumab (v roku 1 do 2 tednov zdravljenja) zniža koncentracijo C-reaktivnega proteina, ki je označevalec vnetja.
Prepare the required number of vials (2 vials for the 300 mg dose). 
Pripravite potrebno število vial (2 viali za odmerek 300 mg).
After using Cosentyx you should not breast-feed for at least 20 weeks after the last dose. 
Po prenehanju uporabe zdravila Cosentyx še najmanj 20 tednov po zadnjem odmerku ne smete dojiti.
Table 1 List of adverse reactions in clinical studies and post-marketing experience 
Preglednica 1 Seznam neželenih učinkov v kliničnih študijah in na osnovi izkušenj uporabe zdravila po prihodu na trg
Cosentyx is available in packs containing one vial. 
Zdravilo Cosentyx je na voljo v pakiranju, ki vsebuje eno vialo.
DO NOT invert the vial. 
Viale NE obračajte na glavo.
IGA mod 2011 “clear” or “almost clear” response n (%) 
odziv IGA mod 2011 "brez znakov" ali "skoraj brez znakov" n (%)
Patients in these studies had a diagnosis of PsA of at least five years. 
Diagnozo psoriatičnega artritisa so imeli bolniki v teh študijah že najmanj 5 let.
Preparing the Cosentyx pre-filled syringe ready for use Note: For a 300 mg dose, prepare 2 pre-filled syringes and inject the contents of both. 
Priprava napolnjene injekcijske brizge z zdravilom Cosentyx na injiciranje Opomba: Za odmerek 300 mg pripravite 2 napolnjeni injekcijski brizgi in injicirajte vsebino obeh.
No pharmacokinetic data are available in patients with renal or hepatic impairment. 
Pri bolnikih z okvaro ledvic ali jeter ni na voljo nobenih farmakokinetičnih podatkov.
Patients with each subtype of PsA were enrolled in these studies, including polyarticular arthritis with no evidence of rheumatoid nodules, spondylitis with peripheral arthritis, asymmetric peripheral arthritis, distal interphalangeal involvement and arthritis mutilans. 
V ti dve študiji so bili vključeni bolniki z vsemi podtipi psoriatičnega artritisa, vključno s poliartikularnim artritisom brez revmatoidnih vozličev, s spondilitisom, s perifernim artritisom, z asimetričnim perifernim artritisom, s prizadetostjo distalnih interfalangealnih sklepov in z mutilirajočim artritisom.
After initial weekly dosing during the first month, time to reach the maximum concentration was between 31 and 34 days based on population pharmacokinetic analysis. 
Po začetnem odmerjanju enkrat na teden v prvem mesecu je bilo po rezultatih analize populacijske farmakokinetike potrebno 31 do 34 dni za doseg najvišje koncentracije v plazmi.
• low blood pressure, which can cause dizziness or light-headedness 
• nizek krvni tlak, ki lahko povzroča omotičnost ali slabost pred izgubo zavesti,
Slowly depress the plunger as far as it will go so that the plunger head is completely between the syringe guard wings. 
Počasi potiskajte bat, dokler gre, tako da se na koncu glava bata povsem usede med krila zapirala brizge.
You should not be given certain types of vaccines (live vaccines) while using Cosentyx. 
V času uporabe zdravila Cosentyx ne smete prejeti nekaterih vrst cepiv (živih cepiv).
In psoriasis studies, the safety and efficacy of secukinumab in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated. 
V študijah niso ocenjevali varnosti in učinkovitosti sekukinumaba v kombinaciji z imunosupresivnim zdravljenjem, kar vključuje tudi biološka zdravila in fototerapijo.
Statistically significant difference in ACR 20 versus placebo was reached at week 3. 
Do statistično značilne razlike pri doseganju odziva ACR 20 v primerjavi z uporabo placeba je prišlo v 3. tednu.
Cases of new or exacerbations of Crohn's disease and ulcerative colitis have been reported. 
Poročani so bili primeri poslabšanja ter na novo nastale Crohnove bolezni in ulceroznega kolitisa.
Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. 
Sekukinumab usmerjeno deluje proti IL-17A in zavira njegovo interakcijo z receptorjem za IL-17A, ki je prisoten na različnih vrstah celic, med drugim tudi na keratinocitih.
After reconstitution: The solution can be used immediately or can be stored at 2°C to 8°C for up to 24 hours. 
Po rekonstituciji: Raztopino je mogoče uporabiti takoj, mogoče pa jo je do 24 ur shranjevati pri temperaturi od 2 °C do 8 °C.
Psoriasis study 2 (FIXTURE) evaluated 1,306 patients. 
V 2. študiji psoriaze (študiji FIXTURE) so ocenjevali 1.306 bolnikov.
By touching them, the syringe guard may be activated too early. 
Z dotikom lahko namreč prezgodaj aktivirate zapiralo brizge.
If necessary, Cosentyx can be left out of the refrigerator for a single period of up to 4 days at room temperature, not above 30°C. 
Če je potrebno, je zdravilo Cosentyx mogoče pustiti izven hladilnika samo enkrat za največ 4 dni pri sobni temperaturi, ki ne presega 30 °C.
There are no adequate data from the use of secukinumab in pregnant women. 
O uporabi sekukinumaba pri nosečnicah ni na voljo ustreznih podatkov.
Slowly release the plunger and allow the syringe guard to automatically cover the exposed needle. 
Počasi spustite bat in pustite, da zapiralo brizge samodejno pokrije izpostavljeno iglo.
• upper respiratory tract infections with symptoms such as sore throat and stuffy nose 
• okužbe zgornjih dihal s simptomi, kot sta vneto grlo oziroma žrelo in zamašen nos
Never leave the syringe lying around where others might tamper with it. Do not shake the syringe. 
Injekcijske brizge nikoli ne puščajte ležati naokoli, da ne bi nanjo naleteli drugi ljudje.
Caution should be exercised when prescribing secukinumab to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. 
Pri predpisovanju sekukinumaba bolnikom z vnetno črevesno boleznijo, kar vključuje Crohnovo bolezen in ulcerozni kolitis, je potrebna previdnost.
After storage at 2°C to 8°C, the solution should be allowed to come to room temperature for approximately 20 minutes before administration. 
Po shranjevanju pri temperaturi med 2 °C in 8 °C je treba raztopino pred apliciranjem približno 20 minut pustiti na sobni temperaturi.
Its colour may vary from colourless to slightly yellow. 
Njena barva lahko variira od brezbarvne do nekoliko rumenkaste.
Tilt the vial to an angle of approx. 45° and gently rotate between the fingertips for approx. 1 minute. 
Vialo nagnite pod kotom približno 45° in jo rahlo sukajte med konicami prstov približno 1 minuto.
If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use adequate contraception while using Cosentyx and for at least 20 weeks after the last Cosentyx dose. 
Če ste ženska v rodni dobi, vam svetujemo, da se zaščitite pred zanositvijo, zato morate v času uporabe zdravila Cosentyx in še najmanj 20 tednov po zadnjem odmerku tega zdravila uporabljati primerno kontracepcijo.
As a precautionary measure, it is preferable to avoid the use of Cosentyx during pregnancy. 
Iz previdnostnih razlogov se je med nosečnostjo uporabi zdravila Cosentyx bolje izogibati.
• abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems) 
• trebušni krči in bolečine, driska, hujšanje ali kri v blatu (znaki težav s črevesjem).